Abstract
what happens to the microbiota after treatment for an adenoma or carcinoma. This study 4 tested the hypothesis that treatment for adenoma or carcinoma alters the abundance of 5 bacterial populations associated with disease to those associated with a normal colon. We Results. There were large changes to the bacterial communities associated with 10 treatment across the three groups. The communities from patients with carcinomas 11 changed significantly more than those with adenoma following treatment (P-value < 12 0.001). There was no significant change in the microbiota between patients with adenoma 13 and advanced adenoma, or between patients with advanced adenoma and carcinoma 14 (P-value > 0.05). Although treatment was associated with intrapersonal changes, the 15 change in the abundance of individual OTUs to treatment was not consistent within 16 diagnosis groups (P-value > 0.05). Because the distribution of OTUs across patients and 17 diagnosis groups was irregular, we used the Random Forest machine learning algorithm 18 to identify groups of OTUs that allowed us to successfully distinguish between pre and 19 post-treatment samples for each of the diagnosis groups. Although the three models 20 successfully differentiated between the pre and post-treatment samples, there was little 21 overlap between the OTUs that were indicative of treatment. Next, we used a larger 22 cohort that contained individuals with normal colons and those with adenomas, advanced 23 adenomas, and carcinomas to determine whether individuals who underwent treatment 24 were more likely to have OTUs associated with normal colons. We again built Random 25 Forest models and measured the change in the positive probability of having one of the 26 2 . CC-BY 4.0 International license peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/138222 doi: bioRxiv preprint first posted online May. 15, 2017; three diagnoses. Only patients who had carcinomas experienced a significant decrease in 27 positive probability of having a lesion after treatment (P-value < 0.05), indicating that the 28 microbial milieu of the colon more closely resembled that of a normal colon. Finally, we 29 tested whether the type of treatment impacted the microbiota of those diagnosed with 30 carcinomas and were unable to detect any significant differences in characteristics of 31 these communities between individuals treated with surgery alone and those treated with 32 chemotherapy or chemotherapy and radiation (P-value > 0.05).
33
Conclusions. By better understanding the response of the microbiota to treatment for 34 adenomas and carcinomas, it is likely that biomarkers will be validated that can be used to 35 quantify the risk of recurrence and the likelihood of survival.
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Background

39
Colorectal cancer (CRC) is the third most common cause of cancer deaths in the 40 United States [1, 2] . Disease mortality has significantly decreased, predominately due to 41 improvements in screening [2] . Despite these improvements, there are still approximately 42 50,000 CRC-related deaths per year in the United States [1] . Current estimates indicate 43 that 20-30% of those who undergo treatment will experience recurrence and 35% of all 44 patients will die within five years [3] [4] [5] . Identification of methods to assess patients' risk of 45 recurrence is of great importance to reduce mortality and healthcare costs. 46 There is growing evidence that the gut microbiota is involved in the progression of CRC. 47 Mouse-based studies have identified populations of Bacteroides fragilis, Escherichia coli, 48 and Fusobacterium nucleatum that alter disease progression [6] [7] [8] [9] [10] . Furthermore, studies 49 that shift the structure of the microbiota through the use of antibiotics or inoculation of 50 germ free mice with human feces have shown that varying community compositions can 51 result in varied tumor burden [11] [12] [13] . Collectively, these studies support the hypothesis 52 that the microbiota can alter the amount of inflammation in the colon and with it the rate of 53 tumorigenesis [14] . 54 Building upon this evidence, several human studies have identified unique signatures of 55 colonic lesions [15] [16] [17] [18] [19] [20] . One line of research has identified community-level differences 56 between those bacteria that are found on and adjacent to colonic lesions 
Results
88
Treatment alters the bacterial community structure of patients diagnosed with 89 colonic lesions. Within our 67-person cohort we tested whether the microbiota of patients 90 with adenoma (N = 22), advanced adenoma (N = 19), or carcinoma (N = 26) had any 91 broad differences between pre and post-treatment samples [ Table 1 ]. The structure of the 92 microbial communities of the pre and post-treatment samples differed, as measured by the 93 θ YC beta diversity metric [ Figure 1A ]. We found that the communities obtained pre and 94 post-treament among the patients with carcinomas changed significantly more than those 95 patients with adenoma (P-value < 0.001). There were no significant differences in the 96 amount of change observed between the patients with adenoma and advanced adenoma 97 or between the patients with advanced adenoma and carcinoma (P-value > 0.05). Next, 98 we tested whether there was a consistent direction in the change in the community 99 structure between the pre and post-treatment samples for each of the diagnosis groups 100 [ Figure 1B -D]. We only observed a consistent shift in community structure for the patients 101 with carcinoma when using a PERMANOVA test (adenoma P-value = 0.999, advanced 102 adenoma P-value = 0.945, and carcinoma P-value = 0.005). Finally, we measured the 103 number of observed OTUs, Shannon evenness, and Shannon diversity in the pre and 104 post-treatment samples and did not observe a significant change for any of the diagnosis 105 groups (P-value > 0.05) [ Table S1 ].
106
The effects of treatment are not consistent across treatment groups. We used two 107 approaches to identify those bacterial populations that change between the two samples 108 for each diagnosis group. First, we sought to identify individual OTUs that could account for 109 the change in overall community structure. However, using a paired Wilcoxon test we were 110 unable to identify any OTUs that were significantly different in the pre and post-treatment where we observed that the treatment had an impact on the overall community structure; 122 however, the effect of treatment was not consistent across patients and diagnosis groups. Difficult to identify effects of specific treatments on the change in the microbiota.
155
The type of treatment that the patients received varied across diagnosis groups. Those 156 with adenomas and advanced adenomas received surgical resection (adenoma, N=4; 157 advanced adenoma, N=4) or polyp removal during colonoscopy (adenoma, N=18; 158 advanced adenoma, N=15) and those with carcinomas received surgical resection (N=12), 159 surgical resection with chemotherapy (N=9), and surgical resection with chemotherapy 160 and radiation (N=5). We focused on the patients with carcinoma and pooled those patients 161 that received chemotherapy with those that received chemotherapy and radiation to 162 improve our statistical power. We did not observe a significant difference in the effect 163 of these treatments on the number of observed OTUs, Shannon diversity, or Shannon 164 evenness (P-value > 0.05). Furthermore, there was not a significant difference in the effect 165 of the treatments on the amount of change in the community structure (P-value = 0.298). 166 Finally, the change in the positive probability was not significantly different between the The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/138222 doi: bioRxiv preprint first posted online May. 15, 2017; probability of carcinoma after treatment. This may reflect an elevated risk of recurrence.
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The 23.08% prevalence of increased carcinoma probability from our study is within the in the top 10% of MDA for each of the 100 different splits. This was then followed with 295 filtering of this list to variables that were only present in more than 50% of these 100 runs. 
application of the pre versus post-treatment models generated the probabilites that the 309 sample was a pre-treatment sample. The application of the normal versus diagnosis 310 models generated the probabilities that the sample was that specific diagnosis (adenoma, 311 advanced adenoma, or carcinoma).
312
Statistical Analysis. The R software package (v3.3.2) was used for all statistical analysis. 
